First hints for leukopenia diagnostic in MS
Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
Numares AG cashes in 20m from EIB
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
Amgen wins race of top `22 deals with $26bn for Horizon thx
According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. This would be the largest acquisition in the company’s history.
European Commission calls for reversal of Illumina’s $7bn Grail merger
The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.
BioNTech and Ryvu Therapeutics enter into global collaboration
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.
Amsterdam Neogene Therapeutics aquired by AstraZeneca
AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. The acquisition delivers an initial payment of $200m on deal closing, and a further up to $120m in both contingent milestones-based and non-contingent consideration.
British AI provider raises $33m in Series A financing
London-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek.
Growing investor interest in biotechnology
Latest investment trends were presented by BIOTECH Insight at the start of the German Equity Forum
C4X Discovery Holdings inks $402m deal with AstraZeneca
C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
EpiEndo Pharmaceuticals pushes COPD candidate
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395